BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Art Pappas joins a Venture Capital Panel at BioContactQuébec 2012 on October 3 in Quebec City.
News | 08. 14. 2012
Art Pappas joins a Venture Capital Panel at BioContactQuébec 2012 on October 3 in Quebec City.
